The target price could deviate by a maximum of $16.64 from the forecast price.
Advertisement
Eli Lilly and Company has dropped 1.43% during the last 3-month period.
The mean estimate for the short term price target for Eli Lilly and Co (NYSE:LLY) stands at $95.79 according to 19 Analysts. The stock had changed -0.54% since market close yesterday. The company net profit margin is 12.00% and gross profit margin is 75.10%. Recent trading put Eli Lilly & Company stock at a -1.97 change from the 50 day moving average, which is -2.39%.
Shares of Eli Lilly were falling on Friday morning, after news about the U.S. Department of Justice conducting an inquiry regarding the company’s “treatment of certain distribution service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid drug rebate program”. The total value of the transaction was worth $2,124,000.
Historically, Eli Lilly & Company has been trading with a 52 week low of 66.25 and a 52 week of high 92.85. (NYSE:MRK)’s shares inclined 0.80% to $55.54. The company has a market cap of $89,322 million and the number of outstanding shares have been calculated to be 1,108,076,550 shares. The company has a one year low of $1.26 and a one year high of $6.80. The Company also has an animal health business segment.
Advertisement
However, analysts are saying the news should have been priced into the shares several days ago. The organization ‘s products are sold in about 120 nations. Medicines, which are discovered or developed by the Company’s human pharmaceutical business segment’s scientists are sold by it. Its animal health business segment runs through the Company’s Elanco division, which produces, develops and markets products for companion animals and food animals. The Company distributes and fabricates its products through facilities in 11 other nations, Puerto Rico and the United States. The Company’s products include Novartis AH products and endocrinology products, neuroscience products, oncology products, cardiovascular goods, products products. In July 2014, Anthera Pharmaceuticals Inc acquired Sollpura (liprotamase), a investigational Pancreatic Enzyme Replacement Therapy (PERT) from Eli Lilly and Company.
